Clinical trials: Gastric Cancer With Peritoneal Dissemination, open to volunteers
Gastric Cancer With Peritoneal Dissemination
An Open Prospective Randomized Clinical Study of the Effectiveness, Tolerability and Safety of a Single Intraperitoneal Use of the Drug "Prospidelong, Powder for the Preparation of a Gel for Topical Use, 1000 mg in Vials, Package No. 1" in Patients With Disseminated Gastric Cancer, Phase I-II
It is planned to conduct an open-label, prospective, randomized clinical study of the efficacy, tolerability and safety of a single intraperitoneal administration of the investigational drug Prospidelong at a dose of 4000 mg…
- Trial name
- ИНТЕЛОН-02 (NCT06232434)
- Testing
- Prospidelong, chemotherapy
- Where
- Belarus
- Volunteers
- 120 people
- Sponsor
- Research Institute for Physical Chemical Problems of the Belarusian State University